The daratumumab group received more maintenance cycles than the lenalidomide-only group (median of 33 vs 21.5), and it had higher rates of completion of 12 cycles (88.5% vs 78.6%).

A median PFS was not reached for daratumumab plus VRd, compared with 52.6 months for the VRd group, while estimated 54-month PFS rates were 68.1% vs 49.5%, respectively.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for ...

Patients received daratumumab and hyaluronidase-fihj administered subcutaneously with carfilzomib and dexamethasone. The primary endpoint was overall response rate. Results showed an overall ...

The daratumumab group also had a 43% lower risk for disease progression or death (HR = 0.57; 95% CI, 0.41-0.79).

Daratumumab was administered subcutaneously at 1800 mg weekly for cycles 1 and 2 followed by every 2 weeks for cycles 3 to 6 and every 4 weeks thereafter. Treatment was stopped after 3 years.

In this low physical function group, daratumumab reduced the risk of death from any cause by 47% (hazard ratio 0.53 [95% CI: 0.40–0.70], P < 0.001) and the risk of cancer progression by 66% ...

Key opinion leaders consider how the approval of daratumumab in the upfront setting for patients with relapsed multiple myeloma has impacted treatment strategies. C. Ola Landgren, MD, PhD: I will ...

Data across nine Phase 3 clinical trials in the frontline and relapsed settings for MM and newly diagnosed light chain (AL) amyloidosis, have shown that daratumumab-based regimens resulted in ...